Abstract | OBJECTIVE: STUDY DESIGN: A Monte Carlo simulation trial was conducted based on a literature review of the PUBMED database (1966 to November 2005). RESULTS: In younger patients (< 35 years), detection of Down syndrome increased by 4, 5, 6, and 7 percentage points when free beta was added to pregnancy-associated plasma protein-A and nuchal translucency compared with 0, 0, 2, and 4 percentage points for intact human chorionic gonadotropin at 9-12 weeks' gestation, respectively. In advanced maternal age patients (> or = 35), inclusion of free beta- human chorionic gonadotropin reduced the false-positive rate by 2.5, 3.1, 3.8, and 4.4 percentage points compared with 0.1, 0.3, 1.0, and 2.2 percentage points for intact human chorionic gonadotropin at 9-12 weeks, respectively. CONCLUSION:
|
Authors | Mark I Evans, David A Krantz, Terrence W Hallahan, Robert S Galen |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 196
Issue 3
Pg. 198-205
(Mar 2007)
ISSN: 1097-6868 [Electronic] United States |
PMID | 17346522
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Biomarkers
- Chorionic Gonadotropin
- Chorionic Gonadotropin, beta Subunit, Human
- Pregnancy-Associated Plasma Protein-A
|
Topics |
- Biomarkers
(blood)
- Chorionic Gonadotropin
(blood)
- Chorionic Gonadotropin, beta Subunit, Human
(blood)
- Clinical Protocols
- Down Syndrome
(diagnosis)
- Female
- Humans
- Pregnancy
- Pregnancy Trimester, First
- Pregnancy-Associated Plasma Protein-A
(analysis)
|